YZYa-Lan Zhou

Ya-Lan Zhou

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ya-Lan Zhou has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Guo-Rui Ruan

    Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People’s Hospital, Peking University, Beijing 100044, China

    3 shared publications
  • Yin Wu

    Department of Haematology Beijing Chaoyang Hospital, Capital Medical University Beijing China

    3 shared publications
  • Yuan Jian

    Department of Haematology Beijing Chaoyang Hospital, Capital Medical University Beijing China

    3 shared publications
  • Yun Leng

    Department of Haematology Beijing Chaoyang Hospital, Capital Medical University Beijing China

    3 shared publications
  • Aijun Liu

    Department of hematology, Beijing Chao-yang hospital, Beijing, China

    2 shared publications
  • Huixing Zhou

    Department of hematology, Beijing Chao-yang hospital, Beijing, China

    2 shared publications

Latest Publications

  • Deep molecular remission and encouraging survival without transplantation: V‐ CAG for arsenic‐resistant relapsed APL

    by Ya‐Lan Zhou, Ting Shi, Chuan‐Ying Geng, Le‐Fu Huang, Yuan Jian, Yun Leng, Yin Wu, Hong‐Hu Zhu

  • Open Access

    Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

    by Ting Shi, Ruicong Xue, Jing Jia, Menghan Liu, Yalan Zhou, Chuanying Geng, Yuan Jian, Ying Tian, Yanru Zhang, Wenjing Li, et al.


  • Open Access

    Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine

    by Hong-Hu Zhu, Ting Shi, Ruicong Xue, Jing Jia, Menghan Liu, Ya-Lan Zhou, Chuan-Ying Geng, Yuan Jian, Ying Tian, Yanru Zhang, et al.

    Patients with acute myeloid leukemia (AML) with CBFB::MYH11 rearrangement who exhibit persistent measurable residual disease (MRD) or molecular relapse following high-dose cytarabine-based chemotherapy have a high risk to overt relapse. In this retrospective single center study, we evaluated the efficacy of the VAG regimen for MRD elimination in this setting. The regimen consisted of venetoclax (400 mg/day, days 1–21), azacitidine (75 mg/m²/day, days 1–7), and granulocyte colony-stimulating factor (5 μg/kg/day, days 1–7). Twenty-seven patients were included (20 with persistent MRD positivity, 7 with molecular relapse; median age, 39 years). Prior to VAG, 96.3% had received intensive chemotherapy (median, 5 cycles) and a median of 2 high-dose cytarabine cycles. The primary endpoint was molecular response, defined as a >0.5-log reduction or conversion to negativity in CBFB::MYH11 transcript levels. After one VAG cycle, median transcript levels declined significantly from 0.120% to 0.0275% (P = 0.0018), representing a median 0.6-log reduction. Among the 26 evaluable patients, 18 (69.2%) achieved an MRD response following VAG treatment after 1–3 cycles of VAG. Median event-free survival and overall survival were not reached. These findings suggest that the VAG regimen represents a clinically meaningful strategy for MRD clearance in CBFB::MYH11-positive AML refractory to HDAC-based consolidation therapy.

  • Open Access

    Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

    by Ya‐Lan Zhou, Jin‐Qiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Li‐Ping Su, Wen‐Ming Chen, Guang‐Zhong Yang

    Backgrounds: Mitoxantrone hydrochloride liposome (Lipo‐MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo‐MIT, and dexamethasone (VMitD) with the primary endpoints being safety and efficacy was performed.Methods: Twenty subjects were enrolled this study, and the dose of Lipo‐MIT was designed to be 12, 16, and 20 mg/m2 at Day 1 combined with bortezomib and dexamethasone.Results: The most common grade 3/4 non‐hematologic adverse event was pneumonia (20%). The most frequently observed grade 3/4 hematologic toxicity included thrombocytopenia (70%), neutropenia (55%), lymphopenia (30%), and anemia (10%). Fifteen subjects received at least one efficacy evaluation, including 60% (9/15) with a very good partial response (VGPR) or better, resulting in an overall response rate (ORR) of 86.7% (13/15).Conclusions: This is the first report about the novel triplet regimen VMitD, including Lipo‐MIT for RRMM, which was well tolerated and demonstrated efficacy. Further studies are required to assess the outcomes more accurately and to evaluate its effectiveness in comparison to other salvage regimens containing proteasome inhibitors and anthracyclines.Trial Registration: ClinicalTrials.gov identifier: NCT05052970


  • Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics

    by Ya-Lan Zhou, Ming-Yue Zhao, Robert Peter Gale, Hao Jiang, Qian Jiang, Li-Xia Liu, Jia-Yue Qin, Shan-Bo Cao, Feng Lou, Lan-Ping Xu, et al.


  • Open Access

    CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia

    by Lei-Ming Cao, Ya-Lan Zhou, Robert Peter Gale, Ya-Zhen Qin, Li-Xin Wu, Ming-Yue Zhao, Xiao-Su Zhao, Yu-Hong Chen, Yu Wang, Hao Jiang, et al.

    Quantification of measurable residual disease (MRD) correlates with the risk of leukemia recurrence in adults with B-cell acute lymphoblastic leukemia (ALL). However, it remains unknown whether collecting data on cysteine and glycine-rich protein 2 (CSRP2) transcript levels, after completing the second course of consolidation, improves prognosis prediction accuracy. A total of 204 subjects with B-cell ALL were tested for CSPR2 transcripts after completing the second course of consolidation using quantitative real-time polymerase chain reaction (qRT-PCR) and divided into high (N = 32) and low (N = 172) CSRP2 expression cohorts. In multivariable analyses, subjects with high expression of CSRP2 had a higher 5-year cumulative incidence of relapse (CIR) (hazard ratio [HR] = 2.57, 95% confidence interval [CI] 1.38-4.76; P = 0.003), lower 5-year relapse-free survival (RFS) (HR = 3.22, 95% CI 1.75-5.93; P < 0.001), and overall survival (OS) (HR = 4.59, 95% CI 2.64-7.99; P < 0.001) in the whole cohort, as well as in the multi-parameter flow cytometry (MPFC) MRD-negative cohort (for CIR, HR = 2.70, 95% CI 1.19-6.12; for RFS, HR = 4.37, 95% CI 1.94-9.85; for OS, HR = 4.90, 95% CI 2.43-9.90; all P < 0.05). Prognostic analysis showed that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could significantly improve the prognosis of patients with high CSRP2 expression (allo-HSCT vs chemotherapy: 5-year CIR, 52% vs 91%; RFS, 41% vs 9%; OS, 38% vs 20%; all P < 0.05). Our data indicate that incorporating data from CSPR2 transcript levels to the MRD-testing at the end of the second course of consolidation therapy enhances prognosis prediction accuracy in adults with B-cell ALL.


  • Open Access

    Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells

    by Ya-Lan Zhou, Qiu-Mei Yao, Jiao Zhou, Yan Chang, Jin-Lan Li, Ya-Zhe Wang, Hong-Ping Wu, Yu-Hong Chen, Yan-Rong Liu, Xiao-Jun Huang, et al.

    Background: Daunorubicin is a traditional chemotherapeutic agent that plays a pivotal role in leukemia therapy. However, the dose-related toxicity remains a considerable challenge. The apoptosis-regulating gene, PDCD5, is downregulated in various tumors, including leukemias, and may provide a potential target for the diagnosis and treatment of leukemia. The purpose of this study was to construct a triple-regulated oncolytic adenovirus carrying a PDCD5 gene expression cassette (SG611-PDCD5) and explore the combined antitumor efficacy of SG611-PDCD5 in combination with low dose daunorubicin on leukemic cells. Materials and methods: A variety of leukemic cell lines, including K562, MEG-01, KG-1a, HL-60, SUP-B15, and BV-173, were cultured according to the providers’ instructions. The insertion and orientation of all recombined plasmids were confirmed by restriction enzyme digestion and PCR. The tumor-selective replication of the constructed conditionally replicating SG611-PDCD5 and its antitumor efficacy in combination with daunorubicin were characterized in leukemic cell lines in vitro and in a nude mouse xenograft model. Cell viability was detected using cell-counting kit-8. Apoptosis was detected in whole living cells using flow cytometry and in paraffin-embedded tumor tissues using a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Results: The triple-regulated CRAd carrying SG611-PDCD5 and nude mouse xenograft models of K562 cells were successfully constructed. In vitro treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner. The Chou-Talalay analysis revealed synergistic anti-proliferative effects in all of the above cell lines. In the nude mice xenograft model, the tumor size in the control, daunorubicin, SG611-PDCD5, and combined treatment groups on day 10 were 170.1±47.8, 111.9±81.1, 60.7±12.3, and 33.2±17.5 mm3, respectively (all PP Conclusion: The findings suggest that combined treatment with SG611-PDCD5 and daunorubicin may be a promising strategy for enhancing chemosensitivity and thus lowering the dose-related toxicity of daunorubicin in leukemia therapy.